| HOME >> MEDICINE >> TECHNOLOGY |
Certain other types of beta amyloid thought to be primarily or exclusively found in amyloid plaque are also increased in blood and CSF of study participants. The antibody produced no change in cognitive scores or in the total amount of amyloid plaque based on IMPY scans. Siemers said that this was expected in a study of this duration.
According to the researchers, brain imaging using MRI and CSF safety assessments showed no evidence of inflammation, bleeding or other side effects throughout the trial. No side effects were identified that appeared to be related to antibody treatment.
"We saw an increase in amyloid beta, which is thought to be bound to LY2062430, in both the blood and cerebrospinal fluid of study participants," Siemers said. "Additionally, after treatment we found a correlation between beta amyloid in blood and the amount of amyloid plaque in brain as determined by IMPY imaging, as well as an increase in blood and CSF in certain types of beta amyloid found in plaques. These biomarker data suggest that amyloid plaques in the brain may begin to 'dissolve' after 12 weeks of treatment with this antibody. We're now planning a Phase III clinical trial of this drug to be started in 2009."
Antidementia Drugs Contribute to Longer Life in People with Alzheimer's
Survival (life span) in people with Alzheimer's is recognized to be shorter than what is expected in cognitively normal seniors and is recognized to be influenced by several factors including age, disease severity, general debility, and gender. Approved antidementia drugs have been shown help with the symptoms of Alzheimer's but their influence on life span is not known.
At ICAD 2008, Susan Rountree, MD, of the Alzheimer's Disease and Memory
Disorders Center of Baylor College of Medicine in Houston, Texas,
'/>"/>
| SOURCE Alzheimer's Association Copyright©2008 PR Newswire. All rights reserved |